Blyth
NYSE:BTHBlyth, Inc. is a United States-based home expressions company. The Company designs, markets and sells various candles and home fragrance products. The Company also designs and markets various health, wellness and beauty products, household convenience items and personalized gifts through the catalog/Internet channel. The Company also focuses on the direct selling and direct marketing channels. The Company's products are sold direct to the consumer under the PartyLite brand and to consumers in the catalog/Internet channel under the Miles Kimball, Walter Drake, Easy Comforts, As We Change, Native Remedies and Exposures brands. The Company sells its products through a network of independent selling consultants primarily throughout the United States and Europe. PartyLite products are sold in approximately 23 countries by over 40,000 PartyLite independent consultants. The Company operates in Plymouth, Massachusetts.
Biomark Diagnostics
CNSX:BUXBioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.
Charles River Laboratories International
NYSE:CRLCharles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.